JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v135,p856)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michael S. Mulligan
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolf, P. S.
Right arrow Articles by Mulligan, M. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wolf, P. S.
Right arrow Articles by Mulligan, M. S.
Related Collections
Right arrow Lung - transplantation
Right arrow Lung - basic science
Right arrowRelated Article

J Thorac Cardiovasc Surg 2008;135:656-665
© 2008 The American Association for Thoracic Surgery

Cardiothoracic Transplantation

Stress-activated protein kinase inhibition to ameliorate lung ischemia reperfusion injury

Patrick S. Wolf, MD, Heather E. Merry, MD, Alexander S. Farivar, MD, Anton S. McCourtie, MD, Michael S. Mulligan, MD*

Division of Thoracic Surgery, University of Washington, Seattle, Wash

Received for publication July 16, 2007; revisions received November 9, 2007; accepted for publication November 26, 2007.

* Address for reprints: Michael S. Mulligan, MD, University of Washington Medical Center, 1959 NE Pacific St, Box 356310, Seattle, WA 98195. (Email: msmmd{at}u.washington.edu).

Objective: Inhibition of cytokines offers modest protection from injury in animal models of lung ischemia–reperfusion. Improved strategies would selectively inhibit the transcriptional activation response to oxidative stress. Mitogen-activated protein kinases (p38, c-jun N-terminal kinase, extracellular signal–regulated kinase) have been shown to be activated after oxidative stress and in animal models of acute inflammatory lung injury. We hypothesized that mitogen-activated protein kinase inhibition would block downstream transcriptional activation, providing robust protection from lung ischemia–reperfusion injury.

Methods: Experimental rats received inhibitors of p38, c-jun kinase, or extracellular signal–regulated kinase before in situ left lung ischemia–reperfusion. Immunohistochemistry localized cellular sites of mitogen-activated protein kinase activation. Several markers of lung injury were assessed. Enzyme-linked immunosorbent assay measured soluble cytokine and chemokine contents. Western blotting assessed mitogen-activated protein kinase phosphorylation. Electromobility shift assays measured transcription factor nuclear translocation.

Results: Immunohistochemistry localized p38 and c-jun kinase activations in positive controls to alveolar macrophages. Extracellular signal–regulated kinase was activated in endothelial and epithelial cells. Animals treated with p38 or c-jun kinase inhibitor demonstrated significant reductions in transcription factor activation and markers of lung injury. Extracellular signal–regulated kinase inhibition was not protective. Western blotting confirmed inhibitor specificity.

Conclusion: Inhibition of p38 and c-jun kinase provided significant protection from injury. The alveolar macrophage appears to be the key coordinator of injury in response to oxidative stress. Therapeutically targeting specific cell population (macrophage) responses to oxidative stress has the potential benefit of reducing lung reperfusion injury severity while leaving host immune responses intact.

Abbreviations and Acronyms AM = alveolar macrophage; AP-1 = activator protein 1; BSA = bovine serum albumin; CINC = cytokine-induced neutrophil chemoattractant; DMSO = dimethylsulfoxide; ERK1/2 = extracellular signal–regulated kinase; IL-1β = interleukin 1β; JNK = c-jun N-terminal kinase; LIRI = lung ischemia–reperfusion injury; MAPK = mitogen-activated protein kinase; MPO = myeloperoxidase; NF-{kappa}B = nuclear factor {kappa}B; PBS = phosphate-buffered saline solution; SAPK = stress-activated protein kinase


Related Article

Discussion
J. Thorac. Cardiovasc. Surg. 2008 135: 664-665. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
J. C. Lee and J. D. Christie
Primary Graft Dysfunction
Proceedings of the ATS, January 15, 2009; 6(1): 39 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. S. McCourtie, A. S. Farivar, S. M. Woolley, H. E. Merry, P. S. Wolf, B. Mackinnon-Patterson, J. C. Keech, E. FitzSullivan, and M. S. Mulligan
Alveolar Macrophage Secretory Products Effect Type 2 Pneumocytes Undergoing Hypoxia-Reoxygenation
Ann. Thorac. Surg., December 1, 2008; 86(6): 1774 - 1779.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.